## TRIPTAN/DIHYDROERGOTAMINE AGENTS PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit

https://www.bcbstx.com/provider/medicaid/star\_kids\_prior\_auth.html

PATIENT AND INSURANCE INFO	RMATION				Today'	's Date:	
Patient Name (First):	Last:					M: DOB (mm/dd/yy):	
Patient Address:		City, State, Zip:			Patient Telephone:		
BCBSTX ID Number:			Group Number:				
PRESCRIBER/CLINIC INFORMATI	ION						
Prescriber Name:				Specialty: Conf		Contact Name:	
Clinic Name:			Clinic	Address:			
City, State, Zip:			Phone #:		Sec	Secure Fax #:	
PLEASE ATTACH ANY ADDITION	AL INFOR	MATION THAT S	HOUL	D BE CONSIDERE	D WITH	1 THIS REQUEST	
Patient's Diagnosis-ICD code plus	description	1:					
Medication Requested:  *Your request will be reviewed for	or the gen	eric equivalent u	nless	Strengtl		uired	
Dosing Schedule:	or the gen	crio equivalent u	111033	Quantity			
	with the re	equested medication	on?			Yes No	
If yes, when was treatment	nt with the	requested medica	ition st	tarted?			
2. Is the patient currently using prophylactic migraine medication? ☐ Yes ☐ No							
If yes, please document a	-						
If no, please provide reas  3. Has medication overuse head:						Yes No	
4. Will the patient be using the re						<del>_</del>	
	-	-				Yes No	
5. Please list the medications the							
brand name, generic, extende	-						
	-	nte(s):				Date(s):	
Date(s):							
6. Please list all reasons for sele						aindications, allergies or history of	
adverse drug reactions.)		_					
7. Please list all other agents the	patient wil	I be taking for the	treatn	nent of the diagnosis	provid	ed	
Prescriber or Authorized Signatu						te:	
Prior Authorization of Benefits is not the treating physician can determine what							
regarding benefits, conditions, limitation	ns, and excl	usions. The submitti	ng pro	vider certifies that the i	nformati		
complete and the requested services a Note: Payment is subject to member el					ent.		
Please fax or mail this form to:	igiomity. 7 tat	Honzallon accorde			NOTICE	: This communication is intended only	
Prime Therapeutics LLC, Clinical Review Department			f	for the use of the individual entity to which it is addressed and may			
2900 Ames Crossing Road Eagan, Minnesota 55121				contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified			
Layan, Millinesota 33121				that any dissemination, distribution or copying of this communication			
				is strictly prohibited. If you have received this communication in			
TOLL FREE				error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime			
Fax: 877.243.6930 Phone: 855.457.1200				Therapeutics via U.S. Mail. Thank you for your cooperation.			